Genocea Biosciences (NASDAQ:GNCAQ) & Editas Medicine (NASDAQ:EDIT) Financial Contrast

Editas Medicine (NASDAQ:EDIT) and Genocea Biosciences (NASDAQ:GNCAQ) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, earnings, analyst recommendations, profitability and risk.

Institutional & Insider Ownership

71.9% of Editas Medicine shares are held by institutional investors. 1.9% of Editas Medicine shares are held by company insiders. Comparatively, 1.6% of Genocea Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Editas Medicine and Genocea Biosciences”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Editas Medicine	$78.12 million	3.58	-$153.22 million	($2.10)	-1.61
Genocea Biosciences	$1.64 million	N/A	-$33.20 million	N/A	N/A

Genocea Biosciences has lower revenue, but higher earnings than Editas Medicine.

Risk & Volatility

Editas Medicine has a beta of 1.99, meaning that its share price is 99% more volatile than the S&P 500. Comparatively, Genocea Biosciences has a beta of 2.44, meaning that its share price is 144% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings for Editas Medicine and Genocea Biosciences, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Editas Medicine	0	7	4	0	2.36
Genocea Biosciences	0	0	0	0	N/A

Editas Medicine currently has a consensus target price of $10.90, indicating a potential upside of 221.53%.

Profitability

This table compares Editas Medicine and Genocea Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Editas Medicine	-288.59%	-62.61%	-42.31%
Genocea Biosciences	N/A	N/A	N/A

Summary

Genocea Biosciences beats Editas Medicine on 5 of the 9 factors compared between the two stocks.

About Editas Medicine

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

About Genocea Biosciences

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts. The plan was later approved as Chapter 11 liquidation on May 11, 2023.